• Subhashini Yaturu.
• Section of Endocrinology, Overton Brooks VA Medical Center/LSU Health Sciences Center, Shreveport, Louisiana 71101-4295, USA.
• Endocr Pract. 2003 Jul 1; 9 (4): 315-20.

ObjectiveTo review the skeletal effects of hydroxy-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) and evaluate the use and potential benefit of statins in the management of osteoporosis.MethodsBackground information on the topic of the effect of statins on bone and fracture risk is presented, and the pertinent published literature is reviewed.ResultsOsteoporosis is the most common bone disease, affecting millions of people worldwide and leading to considerable morbidity, especially when it is not adequately managed. Although statins have primarily been known for their lipid-lowering effects, recent data have documented a potential association between statin use and improvement in fracture risk profile. Some statins have been shown to decrease bone-specific alkaline phosphatase or serum osteocalcin concentrations, but other studies have failed to demonstrate the beneficial effects of these agents. Therefore, additional studies should be undertaken to clarify the mechanism of action.ConclusionObservational studies suggest an association between HMG-CoA reductase inhibitors and reduction in fracture risk. Large randomized controlled clinical trials must be performed to confirm this association.

15 keywords...

hide…